SaRNAs SPIKE SARS COV-2 (E484K; N501Y) have been designed to produce high expression level of Spike SARS COV-2 (E484K; N501Y) protein with enhanced length of duration (see results). OZB saRNAs are produced by in vitro transcription. saRNAs are stabilised at the 5′ end by modified nucleotides capping (Cap1) and contain a poly(A) tail at the 3′ end. Sequences have been optimised to yield improved stability and performance.
OZB saRNA Spike SARS COV-2 (E484K; N501Y) has been constructed based on replicons of positive-sense ((+)-RNA) viruses (Venezuelan equine encephalitis Virus (VEEV)), where the coding sequence of the viral structural proteins is replaced with that of a gene of interest (GOI, here Spike SARS COV-2 (E484K; N501Y)), while retaining the coding sequences of non-structural proteins (nsPs), including the viral RNA-dependent RNA polymerase. Please note that OZB saRNAs encodes also for Puromycin Resistance Cassette, which does not alter the expression of the GOI but can be used for cell selection.
- MRNA78 does not bear any additional nucleotide modifications, molecular weight: 4.16 E+06g/mol
- MRNA79 is modified with 5-methyl-Cytidine (m5C) (100% replacement of Cytidine), molecular weight: 4.21 E+06g/mol
- Ready-to-use stabilised saRNA Spike SARS COV-2 (E484K; N501Y) puroR
- mRNA length: 12911 nt
- Storage: RNAs must be stored at -80°C
- It is recommend to aliquot the RNA solution for a better storage and avoid freeze/thaw cycles
This product has met the following criteria to qualify for the following awards: